-
$21.5M Series A financing round to advance pipeline of next-gen engineered off-the-shelf NK cell therapies
-
Funding round led by current investors Acorn Bioventures and ALSHC; joined by new investor Cormorant Asset Management
-
Financing will drive multiple pre-clinical programs through IND-enabling studies and the continued progression of a GMP manufacturing capability
Breakthrough Solutions for Human Primary Cells & Hematologic Tissue Products
AllCells is a biotechnology company that specializes in biologically relevant, high quality primary cells to enable drug discovery, development, and manufacturing of cell therapies. Leveraging its expertise in hematological and immune cell isolations, combined with on-site whole blood and bone marrow tissue collection operations, AllCells maintains one of the world’s largest and most diverse repositories of donor profiles that can be screened and qualified for biomedical applications.
I had the honor of interviewing Dr. Jay Tong, President and CEO of AllCells. In this interview, we discuss AllCells history, its leadership in blood donor cell collections and hematologic tissue products and the recent opening of its newest facility in Boston, Massachusetts. We also explore the company’s long-term goals and expansion into the cell therapy development space. [Read more…]
BlueCube Bio Becomes Evia Bio™ and Launches iPSC Cryopreservation Solution for Cell & Gene Therapies
MINNEAPOLIS, Dec. 9, 2021 — BlueCube Bio officially announced a company name transition to Evia Bio™, concurrent with the launch of a significant new cryopreservation technology for use in cell and gene therapies utilizing Induced Pluripotent Stem Cells (iPSCs). The osmolyte-based solution increases cell survival above that of commercially available DMSO-based options which is critical for realizing the potential of these therapies. This latest addition expands the company’s portfolio of patented cryopreservation products that also include products for mesenchymal stem cells (MSCs). [Read more…]
AgeX Therapeutics’ Licensee ImStem Biotechnology Does First U.S. Multiple Sclerosis Patient with IMS001
-
ImStem’s MSC Product Candidate IMS001 is Derived from AgeX’s Pluripotent Stem Cell Line ESI-053.
-
IMS001 is an investigational, allogeneic, MSC product derived from a human embryonic stem cell line.
-
It is assumed to be the first hES-MSC based allogeneic cell therapy accepted for clinical trial by the FDA for patients with MS.
denovoMATRIX releases isoMATRIX: Cell and Gene Therapy’s first high-yield MSC isolation technology
DRESDEN, Germany, December 15, 2021 / BioInformant / — denovoMATRIX GmbH, an innovator in cell and gene therapy (CGT) manufacturing, announced the launch of a new technology for bringing down costs and increasing access to high-quality mesenchymal stromal cells (MSCs) for stem cell-based therapies. The technology termed isoMATRIX, is designed to isolate MSCs in xeno-/serum-free conditions with high efficiency and stemness enabling rapid cell expansion for radically reduced cost of goods (COGs) for cell therapy manufacturers.
- « Previous Page
- 1
- …
- 83
- 84
- 85
- 86
- 87
- …
- 201
- Next Page »